The FDA granted fast track designation (FTD) to IBI3003, a first-in-class trispecific antibody, for the treatment of patients ...
Wang S, Xu L, Feng J, et al. Prevalence and Incidence of Multiple Myeloma in Urban Area in China: A National Population-Based Analysis. Front. Oncol. 2019;9:1513.
A panelist highlights promising early-phase trial data on trispecific antibodies targeting multiple myeloma antigens and CD3, emphasizing their high response rates, manageable safety profiles, and ...
SHANGHAI--(BUSINESS WIRE)--ITabMed Ltd., a clinical-stage biotech company in China, announced the IND approval from China National Medical Products Administration (NMPA) for A-337, a CD3-activating bi ...
Magnetic nanoparticles engineered T cells inside living mice and guided them into solid tumors, achieving over 90% tumor ...
Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells—a type of cancer immunotherapy—that can be switched on to varying degrees of intensity and then ...
Adjusted indirect treatment comparison of progression-free survival (PFS) associated with DRd and VRd based on MAIA and SWOG S0777 individual patient-level data. This is an ASCO Meeting Abstract from ...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results